Yes, cystic fibrosis can be missed at birth. Newborn screening catches most cases, but its sensitivity ranges from about 80% to 96% depending on the screening protocol used. That means somewhere between 4 and 20 out of every 100 babies with CF could receive a negative result and go home without a diagnosis. These misses are uncommon in most programs, but they happen often enough that pediatricians are trained to consider CF whenever symptoms appear, regardless of what the newborn screen showed.
How Newborn Screening for CF Works
The screening process starts with a blood sample taken from your baby’s heel shortly after birth. The lab measures a substance called immunoreactive trypsinogen, or IRT, which is a protein released by the pancreas. Babies with CF tend to have higher IRT levels because the disease blocks normal pancreatic function even before birth. Labs typically flag the top 3% of IRT values for further testing.
If IRT is elevated, the sample moves to a second tier: genetic analysis. The lab checks the baby’s DNA for known mutations in the gene responsible for CF. Depending on the program, this panel might test for as few as 24 mutations or as many as 130. If one or two mutations are found, or if the initial IRT was extremely high (top 0.1%) with no mutations detected, some programs collect a second blood sample around three weeks of age to recheck IRT levels. A baby only gets referred for diagnostic testing if this multi-step process raises enough red flags.
Why the Screen Misses Some Cases
False negatives happen for two main reasons: the blood test itself can return a misleadingly low result, or the genetic panel can fail to recognize an uncommon mutation.
On the blood test side, the IRT cutoff is usually set at the 96th percentile. Any baby whose IRT falls below that line, even by a small margin, is reported as negative. Some babies with CF simply produce IRT levels that don’t cross the threshold, particularly in the first day or two of life. Lab errors, though rare, also account for some missed cases. One documented case in Minnesota was the first known false negative in over a decade of screening, discovered only after the infant developed failure to thrive and signs of malabsorption.
The genetic side has a different blind spot. Screening panels are built around mutations validated primarily in people of European descent, because that is historically where CF has been most studied. This creates a significant detection gap for families with South Asian, East Asian, African, or Middle Eastern heritage. None of the commercially available screening panels cover a majority of the harmful mutations found in populations outside of Europe. A baby could have two disease-causing mutations that simply aren’t on the panel, producing a clean genetic result despite having CF.
Atypical CF: A Different Kind of Miss
Some forms of CF are so mild that they wouldn’t necessarily raise alarms even with perfect screening. Atypical CF involves mutations that leave partial protein function intact, often affecting only a single organ rather than the lungs and digestive system together. A person with atypical CF might experience recurrent sinus infections, nasal polyps, mild lung problems, repeated bouts of pancreatitis, or male infertility, sometimes without any respiratory symptoms at all.
These cases frequently go undiagnosed for decades. One published case describes a woman who wasn’t diagnosed until age 57. Even the standard confirmatory test, the sweat chloride test, is unreliable in this group. In one study of adults diagnosed with CF, only 14% had sweat chloride levels above the diagnostic threshold of 60 mmol/L. The majority had levels below 40, well within the range typically considered normal. Their diagnoses ultimately came through genetic testing combined with clinical symptoms, not through the conventional screening pathway.
Symptoms That Should Prompt Further Testing
If your baby passed newborn screening but you’re noticing concerning symptoms, those symptoms still matter. The key warning signs in infancy include:
- Poor weight gain or failure to thrive despite adequate feeding
- Greasy, foul-smelling stools that suggest fat isn’t being absorbed properly
- Persistent cough lasting longer than two weeks, especially if productive
- Salty-tasting skin, which parents sometimes notice when kissing their baby
- Frequent respiratory infections or wheezing that doesn’t resolve
- Constipation or bowel obstruction in the first days of life
The Cystic Fibrosis Foundation emphasizes that primary care providers should know to reassess any infant with persistent cough, constipation, or inadequate weight gain, even after a negative screen. A negative newborn screen lowers the probability of CF but does not eliminate it.
How CF Is Confirmed After a Missed Screen
The gold standard for diagnosis is the sweat chloride test. A small amount of a chemical is applied to the skin (usually the forearm) to stimulate sweating, and the sweat is collected and analyzed. A chloride level of 60 mmol/L or higher confirms CF. Levels between 30 and 59 mmol/L fall into a borderline zone that requires repeat testing or additional workup. Anything below 30 mmol/L makes CF unlikely, though not impossible in atypical cases.
When sweat test results are borderline or don’t match the clinical picture, expanded genetic sequencing can search for mutations beyond the limited panels used in newborn screening. Full sequencing of the CF gene can identify over 2,000 known variants, catching rare mutations that standard panels miss. For babies with an inconclusive result, doctors may classify them as having a CF-related metabolic syndrome and monitor them with regular respiratory cultures, lung function tests, and growth tracking, at least through age eight, to see whether the condition evolves toward a full CF diagnosis.
What a Missed Diagnosis Means for Outcomes
The entire point of newborn screening is early treatment. Babies diagnosed in the first weeks of life can start enzyme supplements, nutritional support, and airway clearance techniques before significant lung damage occurs. When CF is missed at birth, the delay to diagnosis varies widely. Some children are caught within months when symptoms become obvious. Others, particularly those with milder or atypical forms, may not be diagnosed until childhood, adolescence, or even middle age.
A delayed diagnosis doesn’t mean the situation is hopeless. Modern CF therapies, including newer medications that correct the underlying protein defect, have dramatically improved outcomes even for people diagnosed later in life. But earlier diagnosis consistently leads to better lung function and nutritional status in childhood, which is why awareness of false negatives matters. If your child has symptoms that fit, pushing for a sweat test or genetic evaluation is reasonable no matter what the newborn screen said.